Lineage Cell Therapeutics Ratios and Metrics

Market cap in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Aug '26 Aug 10, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Market Cap	286	406	111	191	199	415
Market Cap Growth	27.70%	266.57%	-41.93%	-4.16%	-52.07%	54.10%
Enterprise Value	237.26	351.45	64.1	156.8	143.63	358.34
Last Close Price	1.13	1.67	0.50	1.09	1.17	2.45
Forward PE	-	45.62	45.62	45.62	45.62	45.62
PS Ratio	21.84	27.89	11.66	21.32	13.54	95.65
PB Ratio	4.69	9.11	1.41	3.01	2.71	4.50
P/TBV Ratio	15.06	176.52	4.75	30.43	12.44	11.61
P/FCF Ratio	-	-	-	-	308.06	-
P/OCF Ratio	-	-	-	-	187.92	-
EV/Sales Ratio	18.13	24.14	6.75	17.53	9.77	82.55
EV/FCF Ratio	-	-	-	-	222.33	-
Debt / Equity Ratio	0.02	0.04	0.02	0.03	0.04	0.02
Debt / FCF Ratio	-	-	-	-	6.03	-
Net Debt / Equity Ratio	-0.80	-1.20	-0.58	-0.51	-0.74	-0.60
Net Debt / EBITDA Ratio	1.86	1.49	2.17	1.35	2.48	1.15
Net Debt / FCF Ratio	1.99	2.75	1.91	1.11	-83.56	2.32
Asset Turnover	0.12	0.13	0.09	0.08	0.10	0.03
Quick Ratio	6.44	4.99	3.47	2.02	3.06	2.32
Current Ratio	6.61	5.20	3.65	2.14	3.16	2.37
Return on Equity (ROE)	-62.25%	-105.30%	-26.73%	-32.07%	-32.37%	-46.52%
Return on Assets (ROA)	-24.54%	-29.94%	-20.05%	-20.31%	-15.42%	-34.84%
Return on Invested Capital (ROIC)	-413.84%	-311.47%	-70.19%	-96.20%	-86.28%	-106.74%
Return on Capital Employed (ROCE)	-26.93%	-36.54%	-23.56%	-26.35%	-19.40%	-43.24%
FCF Yield	-	-	-	-	0.32%	-
Buyback Yield / Dilution	-8.73%	-14.95%	-15.94%	-1.69%	-3.22%	-9.64%
Total Shareholder Return	-8.73%	-14.95%	-15.94%	-1.69%	-3.22%	-9.64%

SEC Filings: 10-K · 10-Q